Fezolinetant

A neurokinin 3 receptor antagonist, FDA-approved for moderate to severe hot flashes and night sweats due to menopause.

psilodex.org/m/fezolinetant · data v2026.10.05

Clinical contraindication: None listed; No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence: No psilocybin data
Half-life: ~9.6 h; Approximate, in adults. Source under Interaction below.

Named in state rules?

Not namedColorado

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “Fezolinetant”, v2026.10.05. psilodex.org/m/fezolinetant

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

FDA-approved for

Moderate to severe vasomotor symptoms (hot flashes) due to menopause

Sources [1]

Other safety

Contraindicated with CYP1A2 inhibitors, known cirrhosis, and severe renal impairment; liver tests are required before and during treatment.

About the medication itself, separate from any interaction with psilocybin.

Sources [1]

01 Interaction with psilocybin

No known interaction with psilocybin, and it does not affect enzymes that help the body clear psilocybin. Separately, its label warns of liver injury.

Detail There are no psilocybin data for fezolinetant and no known drug interaction. It is an NK3 receptor antagonist, and its label states it does not inhibit or induce CYP2D6 or CYP3A4. Separately, its label carries a boxed warning for hepatotoxicity (liver damage). Sources [1]

Human data with psilocybin: No psilocybin data; based on its label
Half-life: ~9.6 h (effective) (FDA label, checked 2026-10-04)

Evidence types on this record

No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

1 listed · counted on reports

Liver injury: The label or source warns of liver injury, from raised liver enzymes to liver failure. Liver disease also affects how the body clears psilocin. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-10-04

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

VEOZAH (fezolinetant) tablets (Astellas) · FDA label (DailyMed) — Liver injury: Boxed Warning "Hepatotoxicity has occurred with the use of VEOZAH in the postmarketing setting" | 12.3 "Fezolinetant and ES259564 are not inhibitors of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4." | 12.3 "The effective half-life (t1/2) of fezolinetant is 9.6 hours in women with vasomotor symptoms."

Record history

v2026.10.02First published.
2026-10-04Last reviewed against its sources.

Report an error in this record →